Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study

被引：0

作者：

Kawachi, H. ^{[1
]}

Tamiya, M. ^{[1
]}

Tamiya, A. ^{[2
]}

Ishii, S. ^{[2
]}

Hirano, K. ^{[3
]}

Matsumoto, H. ^{[3
]}

Yokoyama, T. ^{[4
]}

Ishida, T. ^{[4
]}

Ryota, K. ^{[5
]}

Fujimoto, D. ^{[6
]}

Hosoya, K. ^{[6
]}

Suzuki, H. ^{[7
]}

Hirashima, T. ^{[8
]}

Kanazu, M. ^{[9
]}

Sawa, N. ^{[10
]}

Uchida, J. ^{[11
]}

Morita, M. ^{[12
]}

Makio, T. ^{[13
]}

Hara, S. ^{[13
]}

Kumagai, T. ^{[1
]}

机构：

[1] Osaka Int Canc Inst, Thorac Oncol, Osaka, Japan

[2] Kinki Chuo Chest Med Ctr, Internal Med, Sakai, Osaka, Japan

[3] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, Amagasaki, Hyogo, Japan

[4] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[5] Himeji Med Ctr, Resp Med, Himeji, Hyogo, Japan

[6] Kobe City Med Ctr Gen Hosp, Resp Med, Kobe, Hyogo, Japan

[7] Osaka Habikino Med Ctr, Thorac Oncol, Habikino, Japan

[8] Osaka Prefectural Habikino Hosp, Thorac Oncol, Habikino, Japan

[9] Osaka Toneyama Med Ctr, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[10] Toneyama Natl Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[11] Osaka Gen Med Ctr, Resp Med, Osaka, Japan

[12] Kobe City Med Ctr West Hosp, Resp Med, Kobe, Hyogo, Japan

[13] Itami City Hosp, Resp Med, Itami, Hyogo, Japan

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1514P

引用

页数：1

共 50 条

[1] Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
Aguilar, Elizabeth Jimenez
Ricciuti, Biagio
Gainor, Justin F.
Nishino, Mizuki
Adeni, Anika E.
Subegdjo, Safiya
Khosrowjerdi, Sara
Peterson, Rachel
Digumarthy, Subba
Liu, Corinne
Sauter, Jennifer L.
Rizvi, Hira
Arbour, Kathryn Cecilia
Carter, Brett W.
Heymach, John
Altan, Mehmet
Hellmann, Matthew David
Awad, Mark M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya
Akihiro Tamiya
Kazutaka Hosoya
Yoshihiko Taniguchi
Toshihide Yokoyama
Yasushi Fukuda
Katsuya Hirano
Hirotaka Matsumoto
Ryota Kominami
Hidekazu Suzuki
Tomonori Hirashima
Junji Uchida
Mitsunori Morita
Masaki Kanazu
Nobuhiko Sawa
Yoshinori Kinoshita
Satoshi Hara
Toru Kumagai
Daichi Fujimoto
Investigational New Drugs, 2019, 37 : 1266 - 1273
[3] Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Tamiya, Motohiro
Tamiya, Akihiro
Hosoya, Kazutaka
Taniguchi, Yoshihiko
Yokoyama, Toshihide
Fukuda, Yasushi
Hirano, Katsuya
Matsumoto, Hirotaka
Kominami, Ryota
Suzuki, Hidekazu
Hirashima, Tomonori
Uchida, Junji
Morita, Mitsunori
Kanazu, Masaki
Sawa, Nobuhiko
Kinoshita, Yoshinori
Hara, Satoshi
Kumagai, Toru
Fujimoto, Daichi
INVESTIGATIONAL NEW DRUGS, 2019, 37 (06) : 1266 - 1273
[4] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
Kawachi, Hayato
Tamiya, Motohiro
Tamiya, Akihiro
Ishii, Seigo
Hirano, Katsuya
Matsumoto, Hirotaka
Fukuda, Yasushi
Yokoyama, Toshihide
Kominami, Ryota
Fujimoto, Daichi
Hosoya, Kazutaka
Suzuki, Hidekazu
Hirashima, Tomonori
Kanazu, Masaki
Sawa, Nobuhiko
Uchida, Junji
Morita, Mitsunori
Makio, Takeshi
Hara, Satoshi
Kumagai, Toru
INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 211 - 218
[5] Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab'
Kocak, Mehmet Zahid
ACTA ONCOLOGICA, 2021, 60 (04) : 564 - 565
[6] First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
Amrane, Karim
Geier, Margaux
Corre, Romain
Lena, Herve
Leveiller, Guillaume
Gadby, Florence
Lamy, Regine
Bizec, Jean-Louis
Goarant, Eric
Robinet, Gilles
Gouva, Sylvie
Quere, Gilles
Abgral, Ronan
Schick, Ulrike
Bernier, Cyril
Chouaid, Christos
Descourt, Renaud
CANCER MEDICINE, 2020, 9 (07): : 2309 - 2316
[7] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
Hayato Kawachi
Motohiro Tamiya
Akihiro Tamiya
Seigo Ishii
Katsuya Hirano
Hirotaka Matsumoto
Yasushi Fukuda
Toshihide Yokoyama
Ryota Kominami
Daichi Fujimoto
Kazutaka Hosoya
Hidekazu Suzuki
Tomonori Hirashima
Masaki Kanazu
Nobuhiko Sawa
Junji Uchida
Mitsunori Morita
Takeshi Makio
Satoshi Hara
Toru Kumagai
Investigational New Drugs, 2020, 38 : 211 - 218
[8] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
Bureau, Mathilde
Chatellier, Thierry
Perennec, Tanguy
Goronflot, Thomas
Greilsamer, Charlotte
Chene, Anne-Laure
Affi, Raafet
Frampas, Eric
Bennouna, Jaafar
Pons-Tostivint, Elvire
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1747 - 1756
[9] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
Mathilde Bureau
Thierry Chatellier
Tanguy Perennec
Thomas Goronflot
Charlotte Greilsamer
Anne-Laure Chene
Raafet Affi
Eric Frampas
Jaafar Bennouna
Elvire Pons-Tostivint
Cancer Immunology, Immunotherapy, 2022, 71 : 1747 - 1756
[10] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
Kuzminin, A.
Minatta, N.
Bluthgen, M.
Rizzo, M.
Naveira, M.
Wainsztein, V.
Lupinacci, L.
Rizzi, M.
Faura, M.
Perfetti, A.
Recondo, G., Jr.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590

← 1 2 3 4 5 →